Polycystic Kidney, Autosomal Dominant: all 177 studies

Page 2 of 2. Open to participants first (39), then studies with results posted, then the rest; newest registration first within each.

• A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT05521191Phase 1
• Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney DiseaseActive, not recruitingNCT05510115Phase 2
• Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic CystsStatus unknownNCT05500157Not applicable
• Renal Denervation in ADPKD- RDN-ADPKD StudyActive, not recruitingNCT05460169Not applicable
• Intrarenal Microvasculature in ADPKDActive, not recruitingNCT05288998
• Treatment of Vascular Stiffness in ADPKDCompletedNCT05228574Phase 4
• A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKDActive, not recruitingNCT05193981
• Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium AdministrationCompletedNCT05190744Phase 2
• To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy VolunteersCompletedNCT04908462Phase 1
• Daily Caloric Restriction in ADPKDActive, not recruitingNCT04907799Not applicable
• Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney DiseasesCompletedNCT04689074
• Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT04680780Not applicable
• A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT04536688Phase 1
• Time Restricted Feeding in Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT04534985Not applicable
• PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)CompletedNCT04407481
• The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT04363554Not applicable
• Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and SaltStatus unknownNCT04310319Not applicable
• Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT04284657Phase 2
• The Role of Endothelial Dysfunction in Adult Polycystic Kidney DiseaseCompletedNCT04023214
• ADPKD and Peritoneal Dialysis: How Anticipate Peritoneal Pressure?CompletedNCT03970018
• Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney DiseaseCompletedNCT03949894Phase 4
• Outcome of Autosomal Dominant Polycystic Kidney Disease Patients on Peritoneal Dialysis: a National Retrospective Study Based on Two French Registries (the French Language Peritoneal Dialysis Registry and the French Renal Epidemiology and Information Network).CompletedNCT03948113
• Dietary Intervention in ADPKD on TolvaptanCompletedNCT03858439Not applicable
• Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKDCompletedNCT03803124Phase 3
• Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney DiseaseStatus unknownNCT03764605Phase 3
• ADPKD Alterations in Hepatic Transporter FunctionCompletedNCT03717883
• Effect of Venglustat in Patients With Renal ImpairmentCompletedNCT03687554Phase 1
• Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney DiseaseStatus unknownNCT03596957Phase 4
• Tolvaptan-Octreotide LAR Combination in ADPKDCompletedNCT03541447Phase 2
• Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKDCompletedNCT03493802
• Dynamic Measurement of Renal Functional Reserve as a Predictor of Long-Term Renal FunctionStatus unknownNCT03442647Not applicable
• Statin Therapy in Patients With Early Stage ADPKDActive, not recruitingNCT03273413Phase 4
• A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT03102632Not applicable
• Using Preimplantation Genetic Diagnosis in Autosomal Dominant Polycystic Kidney Disease Patients: a Multicenter Clinical TrialCompletedNCT02948179Not applicable
• High Water Intake in Polycystic Kidney DiseaseCompletedNCT02933268Not applicable
• Canadian Medical Assessment of JINARC™ Outcomes RegistryCompletedNCT02925221
• Analysis of Clinical and Molecular Genetic Data Influencing the Evolution and Response to Therapy of ADPKD Patients (Autosomal Dominant Polycystic Kidney Disease)Status unknownNCT02887729
• A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in EuropeStatus unknownNCT02848521
• Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT02776241Not applicable
• The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating PainWithdrawnNCT02746419Not applicable
• Efficacy of Tolvaptan on ADPKD PatientsStatus unknownNCT02729662Not applicable
• Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101TerminatedNCT02616055Phase 2
• Effect of the Aquaretic Tolvaptan on Nitric Oxide SystemCompletedNCT02527863Phase 2
• Clinical Implications of DNA Analysis on ADPKDCompletedNCT02322385
• New Quantitive MRI Parameters in Assessing Kidneys of Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT02250287
• The Eurocyst Initiative: Building a Network of ADPKD Reference Centers Across EuropeStatus unknownNCT02187432
• The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted RecipientsCompletedNCT02134899Phase 3
• Lanreotide In Polycystic Kidney Disease StudyCompletedNCT02127437Phase 3
• Effects of Somatostatin on Liver in ADPKDCompletedNCT02119052Phase 2/3
• Effects of Somatostatin on ADPKD HeartCompletedNCT02119013Phase 2/3
• Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)Status unknownNCT02115659Phase 3
• Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKDCompletedNCT02112136Not applicable
• ADPKD Cohort StudyCompletedNCT02084849
• Renal Sympathetic Denervation for Reduction of Pain and Improvement of Insulin Sensitivity in Adult Polycystic Kidney DiseaseStatus unknownNCT02062671Not applicable
• Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney DiseaseStatus unknownNCT02055079Phase 3
• Ursodeoxycholic Acid as Treatment for Polycystic Liver DiseaseCompletedNCT02021110Phase 2
• Repository Study of Autosomal Dominant Polycystic Kidney DiseaseWithdrawnNCT01988038
• Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression ControlStatus unknownNCT01932450Phase 2
• A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)CompletedNCT01810614Not applicable
• Study of Lanreotide to Treat Polycystic Kidney DiseaseStatus unknownNCT01616927Phase 3
• The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney DiseaseTerminatedNCT01589705
• Observational Study in Patients With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT01430494
• Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal InsufficiencyCompletedNCT01377246Phase 3
• Efficacy Study of Water Drinking on PKD Progression.CompletedNCT01348035
• Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal InsufficiencyTerminatedNCT01223755Phase 2/3
• Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT01114594
• Consortium for Radiologic Imaging Studies of Polycystic Kidney DiseaseCompletedNCT01039987
• Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)Status unknownNCT00890279Phase 2
• Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney DiseaseTerminatedNCT00801268Not applicable
• Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00759369Not applicable
• Adrenal Functions in Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT00598377Not applicable
• Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain StudyCompletedNCT00571909Not applicable
• Lanreotide as Treatment of Polycystic LiversCompletedNCT00565097Phase 2/3
• CCB Safety Study in Treatment of Hypertension of ADPKDStatus unknownNCT00541853Phase 4
• The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT00410007Not applicable
• Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00346918Phase 3
• Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up StudyCompletedNCT00309283Phase 3

← Polycystic Kidney, Autosomal Dominant overview